Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on financial performance, capital structure, governance, and material events for a Nasdaq‑listed biopharmaceutical issuer focused on RNA interference (RNAi) therapeutics.
Investors can review current reports on Form 8‑K, where Alnylam reports quarterly financial results, material financing transactions, and other significant developments. Recent 8‑K filings describe quarterly results for periods in 2025, including discussions of net product revenues from AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, collaboration and royalty revenues, and the use of non‑GAAP financial measures. Other 8‑K filings outline a revolving credit facility, convertible senior note offerings, and partial repurchases of existing convertible notes, giving insight into the company’s liquidity and leverage.
Filings also cover governance and compensation matters, such as changes to the Board of Directors and updates to executive roles and compensation in connection with organizational changes in research and development. These disclosures help readers understand how Alnylam structures its leadership and aligns incentives as it advances its pipeline and commercial portfolio.
Through Stock Titan, users can track ALNY’s SEC submissions as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections of lengthy filings. This includes identifying key points in quarterly and annual reports, highlighting notable items in 8‑Ks, and surfacing information about direct financial obligations, credit agreements, and other events that may affect the company’s risk profile. The filings page is a resource for analyzing how Alnylam reports on its RNAi business, capital markets activity, and corporate governance over time.
ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported an equity award of company common stock. He acquired 158 shares of common stock on February 23, 2026 at a stated price of $0.00 per share as a grant/award.
According to the footnotes, this grant reflects shares issued in recognition of 20 years of continuous employment under a program that provides stock with an aggregate value of $100,000 to each qualifying employee, net of minimum statutory tax withholding. After this award, his directly held common stock totals 21,422 shares.
The filing also reports 537 shares of common stock held indirectly in a managed account, reflecting shares acquired through the company’s 401(k) matching contribution program.
Garg Pushkal reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 24,848 shares.
Greenstreet Yvonne reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 21,167 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 85,662 shares.
Tanguler Tolga reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 5,959 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 31,769 shares.
Fitzgerald Kevin Joseph reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 8,000 shares at a weighted average price of $321.24 per share. Following the reported transactions, holdings were 21,264 shares.
Poulton Jeffrey V. reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 59,802 shares.
An insider of ALNY has filed a notice to sell 2,041 common shares through UBS Financial Services on or about February 17, 2026 on Nasdaq, with an indicated aggregate market value of $677,531.58. The filing shows these shares were acquired on February 12, 2026 via a PSU (performance stock unit) transaction with the issuer.
The insider previously sold 12,128 common shares on November 17, 2025 for $5,483,998.14 and 2,290 common shares on January 13, 2026 for $848,062.57. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Alnylam Pharmaceuticals outlines its RNAi-focused business and long-term "Alnylam 2030" goals in its annual report, targeting at least 25% compound annual total revenue growth and ~30% non-GAAP operating margin by 2030. The company now has six marketed RNAi-based medicines and more than 20 clinical programs, including several in late-stage development across rare diseases, cardiometabolic conditions, and CNS disorders.
To support growth, Alnylam issued $661.3 million of 0.00% Convertible Senior Notes due 2028 and used cash to repurchase about $672.2 million principal of its 1.00% Convertible Senior Notes due 2027 for roughly $1.16 billion. It also established a secured $500 million revolving credit facility, which was undrawn at year-end aside from $17.5 million in letters of credit. Multiple collaborations with Roche, Regeneron, Sanofi, Novartis, Vir and others are intended to expand its pipeline and global reach.
Alnylam Pharmaceuticals reported a strong turnaround for 2025, driven by rapid growth in its RNAi medicines. Total revenues reached $3.71 billion, up 65% from 2024, while net product revenues rose 81% to $2.99 billion, led by AMVUTTRA for ATTR amyloidosis and steady growth in GIVLAARI and OXLUMO.
The company moved from a GAAP net loss of $278.2 million in 2024 to GAAP net income of $313.7 million in 2025; non-GAAP net income was $683.6 million. Fourth-quarter 2025 revenues were $1.10 billion, up 85% year over year, with total net product revenues more than doubling.
Management introduced its "Alnylam 2030" strategy, highlighting durable TTR leadership and long-term innovation, and issued 2026 guidance calling for $4.9–$5.3 billion in net product revenues and $400–$500 million in collaboration and royalty revenue. Cash, cash equivalents and marketable securities were $2.91 billion at year-end, supporting continued pipeline and manufacturing investments.